Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | UGT8 | Q16880 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 3/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564704 | 0.84 | CYP2C9 (0.46) | CYP2C9GRM4PDE4APDE4BCNR1 | |
| SCHEMBL10237749 | 0.79 | CYP2C9 (0.37) | CYP2C9GRM4PDE4APDE4BCNR1 | |
| SCHEMBL566130 | 0.79 | CNR2 (0.41) | CYP2C9GRM4CNR1IRAK4SCN9A | |
| SCHEMBL566218 | 0.76 | PDE4B (0.46) | PDE4APDE4BCNR1 | |
| SCHEMBL565746 | 0.72 | CASP1 (0.50) | SCN9A | |
| SCHEMBL566172 | 0.72 | CNR1 (0.39) | CYP2C9CNR1IRAK4MAPK10MAPK8 | |
| SCHEMBL10186939 | 0.67 | PDE4A (0.34) | GRM4PDE4APDE4B | |
| SCHEMBL565685 | 0.67 | PDE4B (0.52) | PDE4APDE4B | |
| SCHEMBL10186942 | 0.67 | PDE4A (0.35) | GRM4PDE4APDE4BPTGES | |
| SCHEMBL566095 | 0.65 | CNR1 (0.44) | PDE4APDE4BCNR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499570-B2 | Boron containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150376210-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2015-12-31 | — | — | US | disclosed |
| US-9145429-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140200198-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| US-8716478-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120035132-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| WO-2011094450-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC (US) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200198-A1 | BORON-CONTAINING SMALL MOLECULES | BTD, BCL6B, BBOX1 | CYP2C9 3045/4885GRM4 4506/4885PDE4A 1744/4885 |
| US-20120035132-A1 | BORON-CONTAINING SMALL MOLECULES | BTD, BCL6B, BBOX1 | CYP2C9 3045/4885GRM4 4506/4885PDE4A 1744/4885 |
| US-20150376210-A1 | BORON-CONTAINING SMALL MOLECULES | BTD, BCL6B, BBOX1 | CYP2C9 3045/4885GRM4 4506/4885PDE4A 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.